Works matching IS 00126667 AND DT 2024 AND VI 84 AND IP 7

Results: 11
    1
    2
    3

    Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.

    Published in:
    Drugs, 2024, v. 84, n. 7, p. 811, doi. 10.1007/s40265-024-02067-8
    By:
    • Hey, John A.;
    • Abushakra, Susan;
    • Blennow, Kaj;
    • Reiman, Eric M.;
    • Hort, Jakub;
    • Prins, Niels D.;
    • Sheardova, Katerina;
    • Kesslak, Patrick;
    • Shen, Larry;
    • Zhu, Xinyi;
    • Albayrak, Adem;
    • Paul, Jijo;
    • Schaefer, Jean F.;
    • Power, Aidan;
    • Tolar, Martin
    Publication type:
    Article
    4
    5

    Zastaprazan: First Approval.

    Published in:
    Drugs, 2024, v. 84, n. 7, p. 863, doi. 10.1007/s40265-024-02057-w
    By:
    • Blair, Hannah A.
    Publication type:
    Article
    6
    7

    Aprocitentan: First Approval.

    Published in:
    Drugs, 2024, v. 84, n. 7, p. 841, doi. 10.1007/s40265-024-02053-0
    By:
    • Dhillon, Sohita
    Publication type:
    Article
    8

    Givinostat: First Approval.

    Published in:
    Drugs, 2024, v. 84, n. 7, p. 849, doi. 10.1007/s40265-024-02052-1
    By:
    • Lamb, Yvette N.
    Publication type:
    Article
    9

    Sotatercept: First Approval.

    Published in:
    Drugs, 2024, v. 84, n. 7, p. 857, doi. 10.1007/s40265-024-02058-9
    By:
    • Kang, Connie
    Publication type:
    Article
    10
    11